Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.
作者信息
Yoshida Sakiko, Tuscano Emily, Duong Connie, Chung Jong, Li Yueju, Beckett Laurel, Tuscano Joseph M, Satake Noriko
机构信息
a Department of Pediatrics , University of California , Davis , CA , USA.
b Department of Internal Medicine , University of California , Davis , CA , USA.
出版信息
Leuk Lymphoma. 2017 May;58(5):1254-1257. doi: 10.1080/10428194.2016.1235273. Epub 2016 Oct 5.
Abstract
摘要
相似文献
1
Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.抗CD22抗体-单甲基奥瑞他汀E偶联物在前体B细胞急性淋巴细胞白血病临床前异种移植模型中的疗效
Leuk Lymphoma. 2017 May;58(5):1254-1257. doi: 10.1080/10428194.2016.1235273. Epub 2016 Oct 5.
2
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.DCDT2980S，一种抗 CD22-单甲基奥瑞他汀 E 的抗体药物偶联物，是一种治疗非霍奇金淋巴瘤的潜在药物。
Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.
3
Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.激活自噬增强抗体药物偶联物利妥昔单抗单甲基奥瑞他汀 E 的抗肿瘤作用。
Front Immunol. 2018 Aug 3;9:1799. doi: 10.3389/fimmu.2018.01799. eCollection 2018.
4
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.依妥珠单抗：从临床前研发到在 B 细胞急性淋巴细胞白血病中的成功。
Blood Adv. 2019 Jan 8;3(1):96-104. doi: 10.1182/bloodadvances.2018026211.
5
A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.一种基于抗HER2双价抗体和澳瑞他汀E的偶联物靶向HER2阳性癌细胞。
Int J Mol Sci. 2017 Feb 14;18(2):401. doi: 10.3390/ijms18020401.
6
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.CD22 靶向抗体-蓖麻毒素偶联物在人源前 B 细胞急性淋巴细胞白血病异种移植模型中的疗效。
Leuk Res. 2013 Jan;37(1):83-8. doi: 10.1016/j.leukres.2012.09.010. Epub 2012 Oct 4.
7
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.一种新型抗 CD22 蒽环类抗体药物偶联物（ADC），可克服基于 Auristatin 的 ADC 的耐药性。
Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.
8
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.CD123 表达模式及 CD123 靶向抗体药物偶联物（IMGN632）在急性淋巴细胞白血病中的选择性靶向作用。
Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.
9
Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.以单甲基澳瑞他汀E为有效载荷的缬氨酸-丙氨酸基抗体-药物偶联物的研发与特性
Int J Mol Sci. 2017 Aug 25;18(9):1860. doi: 10.3390/ijms18091860.
10
Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.奥英妥珠单抗治疗复发的B细胞急性淋巴细胞白血病
Eur J Haematol. 2017 May;98(5):425-434. doi: 10.1111/ejh.12862. Epub 2017 Mar 9.
引用本文的文献
1
Immune-related adverse events of antibody-based biological medicines in cancer therapy.癌症治疗中基于抗体的生物药物的免疫相关不良反应。
J Cell Mol Med. 2024 Jul;28(13):e18470. doi: 10.1111/jcmm.18470.
2
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.一种新型双特异性 T 细胞衔接器（BiTE），靶向 CD22 和 CD3，具有体外和体内活性，并在急性淋巴细胞白血病（ALL）肿瘤模型中与blinatumomab 协同作用。
Cancer Immunol Immunother. 2023 Sep;72(9):2939-2948. doi: 10.1007/s00262-023-03444-0. Epub 2023 May 29.
3
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.治疗性单克隆抗体及抗体产品：多发性骨髓瘤的当前实践与发展
Cancers (Basel). 2019 Dec 19;12(1):15. doi: 10.3390/cancers12010015.
4
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.抗体药物偶联物在淋巴恶性肿瘤和多发性骨髓瘤临床试验中的应用。
J Hematol Oncol. 2019 Sep 10;12(1):94. doi: 10.1186/s13045-019-0786-6.
本文引用的文献
1
The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.HB22.7-vcMMAE抗体药物偶联物对非霍奇金淋巴瘤小鼠异种移植瘤有效，且全身毒性极小。
Cancer Immunol Immunother. 2016 Oct;65(10):1169-75. doi: 10.1007/s00262-016-1873-y. Epub 2016 Aug 9.
2
New developments for antibody-drug conjugate-based therapeutic approaches.抗体药物偶联物治疗方法的新进展。
Curr Opin Immunol. 2016 Jun;40:14-23. doi: 10.1016/j.coi.2016.02.008. Epub 2016 Mar 7.
3
Acute Lymphoblastic Leukemia in Children.儿童急性淋巴细胞白血病
N Engl J Med. 2015 Oct 15;373(16):1541-52. doi: 10.1056/NEJMra1400972.
4
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.一种新型抗 CD22 蒽环类抗体药物偶联物（ADC），可克服基于 Auristatin 的 ADC 的耐药性。
Clin Cancer Res. 2015 Jul 15;21(14):3298-306. doi: 10.1158/1078-0432.CCR-14-2035. Epub 2015 Apr 3.
5
Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.目前用于治疗淋巴恶性肿瘤的 II 期抗体药物偶联物。
Expert Opin Investig Drugs. 2014 Jul;23(7):911-24. doi: 10.1517/13543784.2014.908184. Epub 2014 Apr 7.
6
Childhood and adolescent cancer statistics, 2014.儿童和青少年癌症统计数据，2014 年。
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103. doi: 10.3322/caac.21219. Epub 2014 Jan 31.
7
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.儿童急性淋巴细胞白血病治疗后的第二恶性肿瘤。
J Clin Oncol. 2013 Jul 1;31(19):2469-76. doi: 10.1200/JCO.2012.47.0500. Epub 2013 May 20.
8
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.DCDT2980S，一种抗 CD22-单甲基奥瑞他汀 E 的抗体药物偶联物，是一种治疗非霍奇金淋巴瘤的潜在药物。
Mol Cancer Ther. 2013 Jul;12(7):1255-65. doi: 10.1158/1535-7163.MCT-12-1173. Epub 2013 Apr 18.
9
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.CD22 靶向抗体-蓖麻毒素偶联物在人源前 B 细胞急性淋巴细胞白血病异种移植模型中的疗效。
Leuk Res. 2013 Jan;37(1):83-8. doi: 10.1016/j.leukres.2012.09.010. Epub 2012 Oct 4.
10
Outcomes after induction failure in childhood acute lymphoblastic leukemia.儿童急性淋巴细胞白血病诱导失败后的结局。
N Engl J Med. 2012 Apr 12;366(15):1371-81. doi: 10.1056/NEJMoa1110169.
Zotero 插件